Cargando…

Immunotherapies for COVID-19: lessons learned from sepsis

Detalles Bibliográficos
Autores principales:	Remy, Kenneth E, Brakenridge, Scott C, Francois, Bruno, Daix, Thomas, Deutschman, Clifford S, Monneret, Guillaume, Jeannet, Robin, Laterre, Pierre-Francois, Hotchkiss, Richard S, Moldawer, Lyle L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195015/ https://www.ncbi.nlm.nih.gov/pubmed/32444269 http://dx.doi.org/10.1016/S2213-2600(20)30217-4

Ejemplares similares

Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19)
por: Laterre, Pierre Francois, et al.
Publicado: (2020)

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial
por: Daix, Thomas, et al.
Publicado: (2023)

New Agents in Development for Sepsis: Any Reason for Hope?
por: Vignon, Philippe, et al.
Publicado: (2020)

Immunotherapy - a potential new way forward in the treatment of sepsis
por: Payen, Didier, et al.
Publicado: (2013)

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression
por: Jeannet, Robin, et al.
Publicado: (2020)

Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis
por: Loftus, Tyler J., et al.
Publicado: (2021)

Older adults show biomarker evidence of PICS after sepsis
por: Mankowski, Robert, et al.
Publicado: (2021)

195 Older adults show biomarker evidence of PICS after sepsis
por: Mankowski, Robert, et al.
Publicado: (2022)

Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Long-Term Survival
por: Mankowski, Robert, et al.
Publicado: (2020)

Dysregulated Immunity and Immunotherapy after Sepsis
por: Darden, Dijoia B., et al.
Publicado: (2021)

Immature granulocytes can help the diagnosis of pulmonary bacterial infections in patients with severe COVID-19 pneumonia
por: Daix, Thomas, et al.
Publicado: (2021)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Elevated malondialdehyde levels in sepsis - something to 'stress' about?
por: Weiss, Scott L, et al.
Publicado: (2014)

Immunological Endotyping of Chronic Critical Illness After Severe Sepsis
por: Fenner, Brittany P., et al.
Publicado: (2021)

Steroid responses in sepsis: some novel thinking that may provide new insight
por: Deutschman, Clifford S
Publicado: (2013)

High prevalence of infections in non-COVID-19 patients admitted to the Emergency Department with severe lymphopenia
por: Baïsse, Arthur, et al.
Publicado: (2022)

Defining critical illness using immunological endotypes in patients with and without of sepsis: A cohort study
por: Balch, Jeremy A., et al.
Publicado: (2023)

Defining critical illness using immunological endotypes in patients with and without sepsis: a cohort study
por: Balch, Jeremy A., et al.
Publicado: (2023)

A Transcriptomic Severity Metric That Predicts Clinical Outcomes in Critically Ill Surgical Sepsis Patients
por: Brakenridge, Scott C., et al.
Publicado: (2021)

Lessons for cross-species viral transmission surveillance from highly pathogenic avian influenza Korean cat shelter outbreaks
por: Kim, Younjung, et al.
Publicado: (2023)

CXCR3 blockade: a novel anti-sepsis approach?
por: Delano, Matthew J, et al.
Publicado: (2012)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
por: Laterre, Pierre-François, et al.
Publicado: (2003)

Limitation of life‑sustaining therapies in critically ill patients with COVID‑19: What lessons to draw?
por: Engrand, Nicolas, et al.
Publicado: (2023)

Phenotypic heterogeneity by site of infection in surgical sepsis: a prospective longitudinal study
por: Stortz, Julie A., et al.
Publicado: (2020)

Towards evidence-based response criteria for cancer immunotherapy
por: Garralda, Elena, et al.
Publicado: (2023)

Passive leg cycling and electrical stimulation cannot preserve strength in sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2019)

Emerging paradigms in sepsis
por: Vincent, Jean-Louis
Publicado: (2022)

De novo natural anti-M alloantibody emergence in severe Coronavirus Disease 2019
por: Jeannet, Robin, et al.
Publicado: (2022)

Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors
por: Custodero, Carlo, et al.
Publicado: (2019)

The new APS: lingering lessons
por: Abman, Steven H.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Bioengineering of bacteria for cancer immunotherapy
por: Nguyen, Dinh-Huy, et al.
Publicado: (2023)

COVID-19 and the anti-lessons of history
por: Peckham, Robert
Publicado: (2020)

Offline: Ukraine and the lessons of Alexander Herzen
por: Horton, Richard
Publicado: (2022)

In neonatal sepsis every catheter matters
por: Ohlin, Andreas, et al.
Publicado: (2021)

Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients
por: Jouan, Youenn, et al.
Publicado: (2020)

Ferroptosis: a new approach for immunotherapy
por: Zeng, Chong, et al.
Publicado: (2020)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Developing Zika vaccines: the lessons for disease X
por: Barrett, Alan D. T.
Publicado: (2018)

Schistosomiasis control: experiences and lessons from China
por: Wang, Longde, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_jpeq4siq5gluj3c2l4a7dcln35